Publication: 346

Publication: 346

Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147.

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 30 (15_suppl) 3514-3514

Meeting Instance:: ASCO 2012
Year:: 2012
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 2105

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Bristol-Myers Squibb, ImClone, Sanofi-Aventis, and Pfizer.
Grants:: NIH Grant CA 25224, NCI K05CA 142885

Corr. Author:
Authors:: Frank A. Sinicrope Michelle R. Mahoney Thomas C. Smyrk Stephen N. Thibodeau Richard M. Goldberg Daniel J. Sargent Garth D. Nelson Steven R. Alberts

Networks:

Study: NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: